We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
+20.01%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$390M
AUM Growth
+$35.6M
Cap. Flow
+$26.9M
Cap. Flow %
6.89%
Top 10 Hldgs %
86.28%
Holding
21
New
3
Increased
–
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$27.7M
2
AKTX
Akari Therapeutics
AKTX
+$7.81M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$7.05M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.58M
2
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$5.24M
3
JUNO
Juno Therapeutics, Inc.
JUNO
+$4.81M

Sector Composition

Rank Sector Weight
1 Healthcare 51.22%
2 Miscellaneous 48.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAC
1
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$139M 35.56%
1,178,474
– –
GWPH
2
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$28.5M 7.31%
311,853
– –
HRTX icon
3
Heron Therapeutics
HRTX
$63M
$26.7M 6.85%
1,095,734
– –
RGNX icon
4
Regenxbio
RGNX
$619M
$20.2M 5.17%
+1,083,454
New +$27.7M
CHRS icon
5
Coherus Oncology
CHRS
$226M
$17.4M 4.47%
870,269
– –
LRMR icon
6
Larimar Therapeutics
LRMR
$421M
$17.3M 4.44%
45,123
– –
LPCN icon
7
Lipocine
LPCN
$18.4M
$15M 3.85%
74,701
– –
ASND icon
8
Ascendis Pharma A/S
ASND
$16.4B
$14.4M 3.68%
811,152
– –
AKTX
9
Akari Therapeutics
AKTX
$17.5M
$12.7M 3.25%
+660
New +$7.81M
ADVM
10
DELISTED
Adverum Biotechnologies
ADVM
$11.4M 2.92%
138,274
– –
ARCT icon
11
Arcturus Therapeutics
ARCT
$460M
$9.06M 2.32%
214,286
– –
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
$8.15M 2.09%
500,000
– –
ORKA
13
Oruka Therapeutics
ORKA
$6.39B
$7.64M 1.96%
7,136
– –
SRRA
14
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$5.13M 1.32%
+6,250
New +$7.05M
STML
15
DELISTED
Stemline Therapeutics, Inc.
STML
$3.99M 1.02%
451,400
– –
OCRX
16
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.22M 0.57%
703,730
– –
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.52B
– –
-373,686
Closed -$5.58M
JUNO
18
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-90,206
Closed -$4.81M
ZSPH
19
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
– –
-100,000
Closed -$5.24M

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q3 2015 Portfolio in Review

As of Q3 2015, VHCP Management held 21 positions worth $390M, up 10% from $354M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

VHCP Management deployed $26.9M of net new capital in Q3 2015, opening 3 new positions. Its largest new stake was Regenxbio: 1,083,454 shares worth $20.2M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 61% a quarter earlier, followed by Miscellaneous.

On the sell side, the most notable exit was BioCryst Pharmaceuticals, an estimated $5.58M sold.

  • VHCP Management's largest Q3 2015 buy was Regenxbio: 1,083,454 shares worth $20.2M.
  • VHCP Management fully exited BioCryst Pharmaceuticals in Q3 2015, selling an estimated $5.58M.
  • VHCP Management's ten largest holdings make up 86% of its $390M portfolio in Q3 2015.
  • VHCP Management opened 3 new positions and closed 3 in Q3 2015.
  • VHCP Management's portfolio value rose 10% quarter-over-quarter to $390M.

Based on VHCP Management's 13F filing for Q3 2015, filed 13 Nov 2015.